indusatumab vedotin (TAK-264) - Takeda, Seattle Genetics
Takeda: Q3 FY 2015 Results (Takeda) - Feb 4, 2016 - “Development terminated due to lack of efficacy” 
Discontinued • Gastric Cancer • Oncology • Pancreatic Cancer
http://www.takeda.com/investor-information/files/qr2015_q3_f_en.pdf
 
Feb 4, 2016
 
.